Background
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral hypoglycemic medications which prevent the breakdown of incretin, resulting in decreased glucagon levels and increased insulin release, thereby reducing blood glucose. This medication class is primarily indicated for management of type 2 diabetes as either monotherapy or in combination with other oral hypoglycemic agents. [1] [2] [3] [4] There are four DPP-4 inhibitors presently available in the US: sitagliptin marketed as Januvia, saxagliptin marketed as Onglyza, linagliptin marketed as Tradjenta, and alogliptin marketed as Nesina. A systematic review showed that adding a DPP-4 inhibitor may be more cost-effective than other medication combinations in patients whose diabetes is not well controlled on monotherapy. 5 However, direct cost comparisons using claims data are lacking.
Objective
To compare post-index direct medical costs for patients prescribed DPP-4 inhibitors in both Medicare and commercial plan cohorts.
Limitations
• Results were subject to limitations inherent in all claims databases, such as missing and miscoded data.
• While Humana is a large national health plan with members throughout the U.S., results may not be generalizable to other populations.
• Medication refills do not ensure the patient consumed their medication.
• The study sample was limited to those with HbA1c results available in the database.
Conclusions
• Although baseline demographics in Medicare and commercial populations were similar across the DPP-4 inhibitor medication groups, patients on linagliptin may have been more complex (i.e., higher DCSI, more insulin use at baseline).
• When controlling for baseline factors, 12-month post-index total healthcare costs were similar across all index DPP-4 medications. Table 2 .
Demographic Characteristics
Medicare patients were older and more likely to be female compared with the commercial cohort. Compared to other DPP-4 inhibitors, patients taking linagliptin had a higher DCSI score, used more insulin, and had higher pre-index costs in both the Medicare and commercial populations. There were no differences in adjusted medical and total health care costs between treatment groups in the Medical and commercial cohorts.
Adjusted pharmacy costs for sitagliptin were significantly higher than linagliptin in the commercial cohort. • The first prescription claim for a DPP-4 inhibitor was defined as the index date and index medication.
• Continuous enrollment was required for the 12 months prior to, and after, the index date.
• Patients without at least one refill of their index medication were excluded from analysis.
Outcomes and Analyses:
• Medicare and commercial populations were analyzed separately.
• Demographic characteristics (age, gender, and geographic region), and the following pre-index clinical and cost characteristics, were described: -A mean Diabetes Complications Severity Index (DCSI) score, which quantifies the severity of 7 diabetes complication categories, was used to asses patients' risk of adverse outcomes, including hospitalizations and death. -Mean hemoglobin A1(HbA1c) levels were calculated from lab results 6 and 18 months after the index date for the subset of patients with available data. -Unadjusted mean pre-index health care costs (sum of plan and patient paid), which were considered a proxy for clinical severity, were reported as total, pharmacy (Rx) and medical costs.
• Post-index costs (in 2013 US dollars) were compared, adjusting for pre-index costs, DCSI, pre-index insulin (defined as a prescription for insulin during the 365 days prior to the index date), age and gender, using generalized linear models (GLMs) and p<0.05.
